Axsome Therapeutics: Strong Patent Protection and Market Expansion Amidst Generic Challenges

Axsome Therapeutics has a positive outlook despite a generic challenge to its drug SYMBRAVO. Analyst Ram Selvaraju at H.C. Wainwright believes the drug's patents are robust and that any litigation would result in a 30-month stay, allowing Axsome to maintain its market exclusivity. SYMBRAVO's rollout is progressing well, and its distinct advantages over existing treatments enhance its market potential. Mizuho Securities also reiterated a Buy rating with a $200 price target.

Axsome Therapeutics, a biopharmaceutical company with a market capitalization of $4.455 billion, has received a Paragraph IV Certification Notice Letter from Apotex Inc., signaling an impending challenge to the market exclusivity of its drug, Symbravo (meloxicam-rizatriptan benzoate). This notice indicates that Apotex has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA), seeking approval to introduce a generic version of Symbravo [1].

Despite this development, Axsome Therapeutics maintains a positive outlook. Analyst Ram Selvaraju at H.C. Wainwright reiterated a Buy rating on Axsome Therapeutics today, setting a price target of $180.00. Selvaraju believes that the patents protecting Symbravo are robust enough to withstand the challenge and that any litigation would likely result in a 30-month stay, allowing Axsome to maintain its market exclusivity in the near term [2].

The ongoing rollout of Symbravo is progressing well, with the product already generating sales and securing payer coverage. The drug’s distinct advantages in terms of safety, tolerability, and efficacy compared to existing treatments further bolster its market potential. Selvaraju anticipates that the coverage for Symbravo will expand significantly, enhancing its commercial prospects. These factors contribute to his confidence in Axsome’s growth trajectory, justifying the Buy rating with a 12-month target price of $180 [2].

In another report released today, Mizuho Securities also reiterated a Buy rating on the stock with a $200.00 price target [2]. The company's strong patent position and the progress of Symbravo's rollout provide a solid foundation for continued growth, despite the generic challenge.

References:
[1] https://www.panabee.com/news/axsome-therapeutics-receives-paragraph-iv-notice-for-symbravo
[2] https://www.tipranks.com/news/ratings/positive-outlook-for-axsome-therapeutics-amidst-symbravos-market-expansion-and-patent-strength-ratings